CytomX Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by CytomX Therapeutics, Inc. on April 22, 2019, reporting events occurring on April 17, 2019. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
On April 17, 2019, Elaine Jones was appointed to the Board of Directors, effective May 1, 2019. She was appointed as a Class II director to fill a vacancy, with an initial term expiring at the 2020 annual meeting of stockholders.
Compensation and Arrangements
- Equity Grant: Ms. Jones received an option to purchase 28,000 shares of common stock under the 2015 Equity Incentive Plan.
- Exercise Price: Set at the closing price of the common stock on May 1, 2019.
- Vesting Schedule: The option vests monthly, with 1/36th of the shares becoming exercisable on each monthly anniversary of the appointment date, contingent on continued service.
- Other Compensation: Ms. Jones will receive standard non-employee director compensation as outlined in the Company's 2018 proxy statement.
- Indemnification: The Company entered into a standard indemnification agreement with Ms. Jones.
The filing confirms no transactions exceeding $120,000 involving Ms. Jones since the beginning of the last fiscal year and no other arrangements regarding her appointment.
Investor Verification Checklist
- Verify the closing stock price on May 1, 2019, to determine the exercise price of the 28,000 share option.
- Review the Company's definitive proxy statement filed on April 26, 2018, for details on standard non-employee director cash compensation.
- Confirm the total number of shares authorized under the 2015 Equity Incentive Plan to assess the impact of this grant.
- Check subsequent filings for the actual vesting schedule execution and any changes to the Board composition.